Skip to main content
Erschienen in: Journal of Endocrinological Investigation 12/2014

01.12.2014 | Short Review

Thymic hyperplasia in patients with Graves’ disease

verfasst von: M. Dalla Costa, F. A. Mangano, C. Betterle

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Graves’ disease (GD) is commonly associated with other autoimmune conditions, and there is also a rare but well documented association between GD and thymic hyperplasia (TH). It is hard to say the real frequency of this latter association because most cases remain asymptomatic and are consequently not thoroughly investigated.

Materials and Methods

We reviewed the literature on GD-related thymus enlargement and found 107 cases published to date. Thymic cancer was only documented in four patients, while the majority of cases were diagnosed as TH. The causative mechanisms behind TH associated with GD have yet to be fully elucidated. Several studies support the hypothesis of a TSH receptor antibody (TRAb) mediating thymic enlargement.

Results

We report on a female GD patient with an incidentally discovered anterior mediastinal mass. Our case is not consistent with the hypothesis of a TRAb-mediated mechanism because the thymus reached its largest volume at the onset of GD and shrank during remission of GD under medical treatment, despite persistently positive TRAb levels.

Conclusion

We support the hypothesis that two different pathogenic mechanisms might be responsible for thymus enlargement: thymic cortical tissue expansion seems to be due to a hyperthyroid state, while lymphoid hyperplasia appears to correlate with immune abnormalities underlying GD.
Literatur
2.
Zurück zum Zitat Wiebolt J, Achterbergh R, Den Boer A, Van Der Leij S, Marsch E, Suelmann B, De Vries R, Van Haeften TW (2011) Clustering of additional autoimmunity behaves differently in Hashimoto’s patients compared with Graves’ patients. Eur J Endocrinol 164:789–794PubMedCrossRef Wiebolt J, Achterbergh R, Den Boer A, Van Der Leij S, Marsch E, Suelmann B, De Vries R, Van Haeften TW (2011) Clustering of additional autoimmunity behaves differently in Hashimoto’s patients compared with Graves’ patients. Eur J Endocrinol 164:789–794PubMedCrossRef
3.
Zurück zum Zitat Halsted WS (1914) Significance of the thymus gland in Graves’ disease. Bull Johns Hopkins Hosp 25:223–224 Halsted WS (1914) Significance of the thymus gland in Graves’ disease. Bull Johns Hopkins Hosp 25:223–224
4.
5.
Zurück zum Zitat Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M (1996) Thymic hyperplasia in patients with Graves’ disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 98:2228–2234PubMedCentralPubMedCrossRef Murakami M, Hosoi Y, Negishi T, Kamiya Y, Miyashita K, Yamada M, Iriuchijima T, Yokoo H, Yoshida I, Tsushima Y, Mori M (1996) Thymic hyperplasia in patients with Graves’ disease. Identification of thyrotropin receptors in human thymus. J Clin Invest 98:2228–2234PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Nakamura S (2012) Thymic enlargement in two cases of Graves’ disease. Internal Med 51:673–674CrossRef Nakamura S (2012) Thymic enlargement in two cases of Graves’ disease. Internal Med 51:673–674CrossRef
7.
Zurück zum Zitat Michie W, Gunn A (1966) The thyroid, the thymus and autoimmunity. Br J Clinic Pract 20:9–13 Michie W, Gunn A (1966) The thyroid, the thymus and autoimmunity. Br J Clinic Pract 20:9–13
8.
Zurück zum Zitat Michie W, Beck JS, Mahaffy RG, Honein EF, Fowler GB (1967) Quantitative radiological and histological studies of the thymus in thyroid disease. Lancet 1:691–695PubMedCrossRef Michie W, Beck JS, Mahaffy RG, Honein EF, Fowler GB (1967) Quantitative radiological and histological studies of the thymus in thyroid disease. Lancet 1:691–695PubMedCrossRef
9.
Zurück zum Zitat Deforges-Bullet V, Petit-Aubert G, Collet-Gaudillat C, Cerceau R, Fraleu-Louer B, Meckenstock R, Greder A, Cordoliani Y, Beressi JP (2011) Thymic hyperplasia and Graves’ disease: a non-fortuitous association. Case report and review of literature. Annales d’Endocrinologie 72:304–309CrossRef Deforges-Bullet V, Petit-Aubert G, Collet-Gaudillat C, Cerceau R, Fraleu-Louer B, Meckenstock R, Greder A, Cordoliani Y, Beressi JP (2011) Thymic hyperplasia and Graves’ disease: a non-fortuitous association. Case report and review of literature. Annales d’Endocrinologie 72:304–309CrossRef
10.
Zurück zum Zitat Kubicky RA, Faerber EN, Chadarevian JP, Wu S, Rezvani I, De Luca F (2010) An adolescent with a mediastinal mass, diagnosed with Graves’ disease and thymic hyperplasia. Pediatrics 125:433–437CrossRef Kubicky RA, Faerber EN, Chadarevian JP, Wu S, Rezvani I, De Luca F (2010) An adolescent with a mediastinal mass, diagnosed with Graves’ disease and thymic hyperplasia. Pediatrics 125:433–437CrossRef
11.
Zurück zum Zitat Takami K, Hideyasu O, Higashiyama M, Maeda J, Okami J, Oda k, Tsujinaka T, Kodama K (2009) A case report of large thymic hyperplasia associated with hyperthyroidism. Ann Thorac Cardiovasc Surg 15:404–407PubMed Takami K, Hideyasu O, Higashiyama M, Maeda J, Okami J, Oda k, Tsujinaka T, Kodama K (2009) A case report of large thymic hyperplasia associated with hyperthyroidism. Ann Thorac Cardiovasc Surg 15:404–407PubMed
12.
Zurück zum Zitat Suh H, Rosen JE, Doherty GM, Sauders BD, McAneny D (2013) Graves’ disease and thymic hyperplasia. Surgery 154:1473–1477 Suh H, Rosen JE, Doherty GM, Sauders BD, McAneny D (2013) Graves’ disease and thymic hyperplasia. Surgery 154:1473–1477
14.
15.
Zurück zum Zitat Nguyen HD, Galitz MS, Clark DD (2011) Visual vignette. What is the diagnosis? Thymic hyperplasia associated with Graves disease. Endocr Pract 17:833PubMedCrossRef Nguyen HD, Galitz MS, Clark DD (2011) Visual vignette. What is the diagnosis? Thymic hyperplasia associated with Graves disease. Endocr Pract 17:833PubMedCrossRef
16.
Zurück zum Zitat Hamzaoui A, Kilii R, Salem R, Kochtali I, Golli M, Mahjoub S (2012) Thymic hyperplasia in a patient with Graves’ disease. Int Arch Med 9:5–6 Hamzaoui A, Kilii R, Salem R, Kochtali I, Golli M, Mahjoub S (2012) Thymic hyperplasia in a patient with Graves’ disease. Int Arch Med 9:5–6
17.
Zurück zum Zitat Kotwal N, Singh Y, Menon A, Behera V (2013) Thymic hyperplasia in Graves’ disease. Indian J Andorinol Metab 17:521–523CrossRef Kotwal N, Singh Y, Menon A, Behera V (2013) Thymic hyperplasia in Graves’ disease. Indian J Andorinol Metab 17:521–523CrossRef
18.
Zurück zum Zitat Levy Y, Afek A, Sherer Y, Bar-Dayan Y, Shibi R, Kopolovic J, Shoenfeld Y (1998) Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum 28:73–79PubMedCrossRef Levy Y, Afek A, Sherer Y, Bar-Dayan Y, Shibi R, Kopolovic J, Shoenfeld Y (1998) Malignant thymoma associated with autoimmune diseases: a retrospective study and review of the literature. Semin Arthritis Rheum 28:73–79PubMedCrossRef
19.
Zurück zum Zitat Lee BW, Ihm SH, Shin HS, Yoo HJ (2008) Malignant thymoma associated with myasthenia gravis, Graves’ disease, and SIADH. Intern Med 47:1009–1012PubMedCrossRef Lee BW, Ihm SH, Shin HS, Yoo HJ (2008) Malignant thymoma associated with myasthenia gravis, Graves’ disease, and SIADH. Intern Med 47:1009–1012PubMedCrossRef
20.
Zurück zum Zitat Boyd JD, Juskeviucius R (2012) Mediastinal neoplasm in patients with Graves’ disease: a possible link between sustained hyperthyroidism and thymic neoplasia? Thyr Res 5:5PubMedCentralPubMedCrossRef Boyd JD, Juskeviucius R (2012) Mediastinal neoplasm in patients with Graves’ disease: a possible link between sustained hyperthyroidism and thymic neoplasia? Thyr Res 5:5PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Nakamura T, Murakami M, Horiguchi H, Nagasaka S, Ishibashi S, Mori M, Ishikawa SE (2004) A case of thymic enlargement in hyperthyroidism in a young woman. Thyroid 14:307–310PubMedCrossRef Nakamura T, Murakami M, Horiguchi H, Nagasaka S, Ishibashi S, Mori M, Ishikawa SE (2004) A case of thymic enlargement in hyperthyroidism in a young woman. Thyroid 14:307–310PubMedCrossRef
22.
Zurück zum Zitat D’Souza S, Patel P, Hageman JR, Deplewski D (2014) An adolescent with Graves’ disease and thymic hyperplasia. Pediatr Ann 43:65–68CrossRef D’Souza S, Patel P, Hageman JR, Deplewski D (2014) An adolescent with Graves’ disease and thymic hyperplasia. Pediatr Ann 43:65–68CrossRef
23.
Zurück zum Zitat Baron RL, Lee JK, Sagel SS, Peterson RR (1982) Computed tomography of the normal thymus. Radiology 142:121–125PubMedCrossRef Baron RL, Lee JK, Sagel SS, Peterson RR (1982) Computed tomography of the normal thymus. Radiology 142:121–125PubMedCrossRef
24.
Zurück zum Zitat Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M (2014) Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. Am J Roentgenol 202:471–478CrossRef Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M (2014) Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. Am J Roentgenol 202:471–478CrossRef
25.
Zurück zum Zitat Takahashi K, Inaoka T, Murakami N, Hirota H, Iwata K, Nagasawa K, Yamada T, Mineta M, Aburano T (2003) Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. Am J Roentgenol 180:1265–1269CrossRef Takahashi K, Inaoka T, Murakami N, Hirota H, Iwata K, Nagasawa K, Yamada T, Mineta M, Aburano T (2003) Characterization of the normal and hyperplastic thymus on chemical-shift MR imaging. Am J Roentgenol 180:1265–1269CrossRef
26.
Zurück zum Zitat Inaoka T, Takahashi K, Mineta M, Yamada T, Shuke N, Okizaki A, Nagasawa K, Sugimori H, Aburano T (2007) Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology 43:869–876CrossRef Inaoka T, Takahashi K, Mineta M, Yamada T, Shuke N, Okizaki A, Nagasawa K, Sugimori H, Aburano T (2007) Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology 43:869–876CrossRef
27.
Zurück zum Zitat McIver B, Morris JC (1998) The pathogenesis of Graves’ disease. Endocrol Metab Clin North Am 27:73–89CrossRef McIver B, Morris JC (1998) The pathogenesis of Graves’ disease. Endocrol Metab Clin North Am 27:73–89CrossRef
28.
Zurück zum Zitat Van Herle AJ, Chopra IJ (1971) Thymic hyperplasia in Graves’ disease. J Clin Endocrinol Metab 32:140–146PubMedCrossRef Van Herle AJ, Chopra IJ (1971) Thymic hyperplasia in Graves’ disease. J Clin Endocrinol Metab 32:140–146PubMedCrossRef
29.
Zurück zum Zitat Hassman R, Weetman AP, Gunn C, Stringer BM, Wynford-Thomas D, Hall R, McGregor A (1985) The effects of hyperthyroidism on experimental autoimmune thyroiditis in the rat. Endocrinology 116:1253–1258PubMedCrossRef Hassman R, Weetman AP, Gunn C, Stringer BM, Wynford-Thomas D, Hall R, McGregor A (1985) The effects of hyperthyroidism on experimental autoimmune thyroiditis in the rat. Endocrinology 116:1253–1258PubMedCrossRef
31.
Zurück zum Zitat Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami S, Oosuga I, Wada S, Katayama S (1998) Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 83:3908–3912PubMed Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami S, Oosuga I, Wada S, Katayama S (1998) Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J Clin Endocrinol Metab 83:3908–3912PubMed
32.
Zurück zum Zitat Figueroa-Vega N, Sanz-Cameno P, Moreno. Otero R, Sanchez-Madrid F, Gonzales-Amaro R, Marazuela M (2009) Serum levels of angiogenetic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab 94:1145–1153PubMedCrossRef Figueroa-Vega N, Sanz-Cameno P, Moreno. Otero R, Sanchez-Madrid F, Gonzales-Amaro R, Marazuela M (2009) Serum levels of angiogenetic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab 94:1145–1153PubMedCrossRef
33.
Zurück zum Zitat Murakami M, Hosoi Y, Araki O, Morimura T, Imamura M, Ogiwara T, Mizuma H, Mori M (2001) Expression of thyreotropin receptors in rat thymus. Life Sci 68:2781–2787PubMedCrossRef Murakami M, Hosoi Y, Araki O, Morimura T, Imamura M, Ogiwara T, Mizuma H, Mori M (2001) Expression of thyreotropin receptors in rat thymus. Life Sci 68:2781–2787PubMedCrossRef
34.
Zurück zum Zitat Wortsman J, McConnachies P, Baker J, Burman K (1988) Immunoglobulins that cause thymocyte proliferation from a patient with Graves’ disease and an enlarged thymus. Am J Med 85:117–121PubMedCrossRef Wortsman J, McConnachies P, Baker J, Burman K (1988) Immunoglobulins that cause thymocyte proliferation from a patient with Graves’ disease and an enlarged thymus. Am J Med 85:117–121PubMedCrossRef
35.
Zurück zum Zitat Popoveniuc G, Sharma M, Devdhar M, Wexler JA, Carroll NM, Wartofsky L, Burman KD (2010) Graves’ disease and thymic hyperplasia: the relationship of thymic volume to thyroid function. Thyroid 9:1015–1018CrossRef Popoveniuc G, Sharma M, Devdhar M, Wexler JA, Carroll NM, Wartofsky L, Burman KD (2010) Graves’ disease and thymic hyperplasia: the relationship of thymic volume to thyroid function. Thyroid 9:1015–1018CrossRef
36.
Zurück zum Zitat Fabris N, Mocchegani E, Mariotti S, Pacini F, Pinchera A (1986) Thyroid function modulates thymic endocrine avtivity. J Clin Endocrinol Metab 62:474–478PubMedCrossRef Fabris N, Mocchegani E, Mariotti S, Pacini F, Pinchera A (1986) Thyroid function modulates thymic endocrine avtivity. J Clin Endocrinol Metab 62:474–478PubMedCrossRef
37.
Zurück zum Zitat Simpson JG, Gray ES, Michies W, Becks JS (1975) The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. Clin Exp Immunol 22:249–255PubMedCentralPubMed Simpson JG, Gray ES, Michies W, Becks JS (1975) The influence of preoperative drug treatment on the extent of hyperplasia of the thymus in primary thyrotoxicosis. Clin Exp Immunol 22:249–255PubMedCentralPubMed
38.
Zurück zum Zitat Volpé R (1979) Auto-immunity in the Endocrine System. Springer, Berlin Volpé R (1979) Auto-immunity in the Endocrine System. Springer, Berlin
39.
Zurück zum Zitat Savino W, Dardenne M (2000) Neuroendocrine control of thymus physiology. Endocr Rev 21:412–413PubMed Savino W, Dardenne M (2000) Neuroendocrine control of thymus physiology. Endocr Rev 21:412–413PubMed
40.
Zurück zum Zitat Weetman AP, McGregor AM, Hall R (1984) Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin Endocrinol 21:163–172CrossRef Weetman AP, McGregor AM, Hall R (1984) Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease. Clin Endocrinol 21:163–172CrossRef
Metadaten
Titel
Thymic hyperplasia in patients with Graves’ disease
verfasst von
M. Dalla Costa
F. A. Mangano
C. Betterle
Publikationsdatum
01.12.2014
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 12/2014
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-014-0157-7

Weitere Artikel der Ausgabe 12/2014

Journal of Endocrinological Investigation 12/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.